Zobrazeno 1 - 6
of 6
pro vyhledávání: '"Piet Vercauter"'
Autor:
Elien Derveaux, Melvin Geubbelmans, Maarten Criel, Ingel Demedts, Ulrike Himpe, Kurt Tournoy, Piet Vercauter, Erik Johansson, Dirk Valkenborg, Karolien Vanhove, Liesbet Mesotten, Peter Adriaensens, Michiel Thomeer
Publikováno v:
Cancers; Volume 15; Issue 7; Pages: 2127
Citation: Derveaux, E.; Geubbelmans, M.; Criel, M.; Demedts, I.; Himpe, U.; Tournoy, K.; Vercauter, P.; Johansson, E.; Valkenborg, D.; Vanhove, K.; et al. Simple Summary: The initiation of non-small-cell lung cancer (NSCLC) causes significant changes
Autor:
Pham Anh Hong Nguyen, Luc Verbeke, Roel Beelen, Christophe Dooms, Kurt G. Tournoy, Piet Vercauter
Publikováno v:
Respiration. 97:310-318
Background: In patients with locally advanced lung cancer treated with concurrent chemoradiation, outcome measurements have been mostly limited to survival. Objectives: We aimed to measure outcomes that matter to these patients beyond survival in a g
Autor:
Luc Van Zandweghe, Daniella Galdermans, K Pat, Isabelle Fabry, Ingel K. Demedts, Isabelle Declercq, Rika Van Herreweghe, Michiel Thomeer, Kurt G. Tournoy, Patrick Alexander, Sofie De Craene, Valerie Van Damme, Heidi Marien, Luc Vanmaele, Nele De Brucker, Paul Germonpré, Piet Vercauter, Rob Schildermans, Sofie Derijcke, Rebecca De Pauw, Elke Govaerts, Karl Govaert
Publikováno v:
Lung Cancer. 115:49-55
In patients with refractory or recurrent non-small-cell lung cancer (NSCLC) after first line chemotherapy, phase III trials showed superiority of nivolumab, an IgG4 programmed death-1 immune-checkpoint-inhibitor antibody, over docetaxel. We evaluated
Autor:
Diether Lambrechts, Guy Berchem, Peter Vuylsteke, Sebahat Ocak, Marc Lambrechts, Sylvia De Brakeleer, Daniella Galdermans, Jacques De Greve, Lynn Decoster, Erik Teugels, Bram Boeckx, Lore Decoster, Thomas Van Brussel, Koen Deschepper, Patrick Alexander, Piet Vercauter, Rajendra Bahadur Shahi, Dominiek Smeets, Nadia Cappoen
Publikováno v:
International journal of cancer, Vol. 146, no. 11, p. 3207-3218 (2020)
Lung cancer is the number one cause of cancer-related death worldwide with cigarette smoking as its major risk factor. Although the incidence of lung cancer in never smokers is rising, this subgroup of patients is underrepresented in genomic studies
Autor:
Claus Vogelmeier, Rob Janssen, Christel Haenebalcke, Marko Topalovic, Nilakash Das, Emiel F.M. Wouters, Huib A. M. Kerstjens, Pierre-Régis Burgel, Christophe Pison, Renaud Louis, Marc Schlesser, Piet Vercauter, Giuseppe Liistro, Eric Derom, Wim Janssens, Vincent Ninane, Jokke Wynants, Marc Daenen
Publikováno v:
Clinical Problems.
Introduction: The use of pulmonary function tests (PFT) is built on an expert opinion. PFT interpretation relies on the recognition of patterns but scarcely leads to a specific respiratory disease diagnosis. We aimed to explore the accuracy and inter
Autor:
M. Schuler, J.C.-H. Yang, K. Park, J.-H. Kim, J. Bennouna, Y.-M. Chen, C. Chouaid, F. De Marinis, J.-F. Feng, F. Grossi, D.-W. Kim, X. Liu, S. Lu, J. Strausz, Y. Vinnyk, R. Wiewrodt, C. Zhou, B. Wang, V.K. Chand, D. Planchard, SaiHong Ignatius Ou, David Planchard, Keunchil Park, Martin Schuler, James Yang, Vikram Chand, Klaus Rohr, Claudia Bagnes, Claudio Marcelo Martin, Gonzalo Recondo, Juan Jose Zarba, Cesar Blajman, Martín Richardet, Sue-Anne McLachlan, Phillip Parente, Craig Underhill, Catherine Crombie, Paul Mainwaring, Richard Greil, Yves Humblet, Frédérique Bustin, Luciano Carestia, Danny Galdermans, Marc Lambrechts, Laetitia Delval, Piet Vercauter, Caicun Zhou, Jin Wang, Cheng Huang, Xiaoyan Lin, Yilong Wu, Xiaoqing Liu, Ying Cheng, Shukui Qin, Jifeng Feng, Jianjin Huang, Yiping Zhang, Shun Lu, Manuela Zereu, Bernardo Garicochea, Cyntia Albuquerque Zadra, Henrik Riska, Tuomo Alanko, Jacques Cadranel, Christos Chouaid, Gérard Zalcman, Denis Moro Sibilot, Maurice Perol, Jaafar Bennouna, Pierre Fournel, Radj Gervais, Maciej Rotarski, Bruno Coudert, Michael Thomas, Thomas Wehler, Martin Faehling, Ulrich Keilholz, Eckart Laack, Joachim von Pawel, Rudolf Huber, Nicolas Dickgreber, Rainer Wiewrodt, Zsuzsanna Mark, Sandor Tehenes, Janos Strausz, Veronika Sarosi, Kumar Prabhash, Minish Jain, Srinivasan Venkatesan, Lalit Sharma, Hemant Dadhich, Rajnish Vasant Nagarkar, Amir Onn, Maya Gottfried, Solomon Stemmer, Maria Rita Migliorino, Francesco Grossi, Paolo Bidoli, Alessandra Bearz, Cesare Gridelli, Carlo Milandri, Marco Platania, Giovanni Luca Ceresoli, Giorgio Cruciani, Francisco Gutierrez Delgado, José Luis Gonzalez Perez, Gabriela Alvarado Luna, Othon Padilla Baca, J.G.J.V. Aerts, J.A. Stigt, A.M.C. Dingemans, G.J.M. Herder, S.J.M. Gans, Jorge Fernando Salas Sánchez, Renzo Luzgardo Alvarez Barreda, Wilbert Rodriguez Pantigoso, Osbert Luis Mejia Palomino, Piotr Jaskiewicz, Andrzej Kazarnowicz, Piotr Serwatowski, Aleksandra Szczesna, Jacek Jassem, Vladimir Lubennikov, Nina Karaseva, Sergey Orlov, Yuri Ragulin, Pilar Garrido, José Luis González Larriba, Carlos Camps, Rosario García Campelo, Pilar Lianes, Manuel Cobo, Enriqueta Felip, Dong-Wan Kim, Sang-We Kim, Joo-Hang Kim, Ji-Youn Han, Young-Chul Kim, Chih-Hsin Yang, Te-Chun Hsia, Yuh-Min Chen, Ying-Huang Tsai, Gee-Chen Chang, Thomas Chang-Yao Tsao, Wu-Chou Su, Ming-Shyan Huang, Ching-Liang Ho, Ruey-Kuen Hsieh, Yuriy Vinnyk, Oleksandr Popovych, Olga Ponomarova, Igor Bondarenko, Iryna Polishchuk, Riyaz Shah, Sanka Mitra, Sanjaykumar Popat, James Spicer, Elizabeth Toy, Toby Talbot, Emma Brown, Sunil Upadhyay, Yvonne Summers, Jayne Gurtler, Luis Meza, John Thropay
Background: Afatinib has demonstrated clinical benefit in patients with non-small-cell lung cancer progressing after treatment with erlotinib/gefitinib. This phase III trial prospectively assessed whether continued irreversible ErbB-family blockade w
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::cf515edf6f94f014c68f3cf563cb2ea0
http://hdl.handle.net/11383/2118727
http://hdl.handle.net/11383/2118727